Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.
Non-Hodgkin Lymphoma
Conditions: official terms
Lymphoma - Lymphoma, Non-Hodgkin
Study Type
Study Phase
Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: oxaliplatin
Type: Drug
Overall Status
Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of patients with refractory or relapsing non-Hodgkin lymphoma.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Patients 18 years or above at the time of inclusion.

2. Documented CD20+ NHL, refractory or relapsing after first line chemotherapy.

3. No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab.

Exclusion Criteria:

1. Other types of non-Hodgkin lymphoma

2. Pregnancy and lactation.

3. Patient unable to give written informed consent.

4. Contra-indication ou intolerance to any of the components of the RGDOx chemotherapy.
CHA Hôpital de l'Enfant-Jésus
Québec, Quebec, Canada
Status: Recruiting
Contact: Linda Vallée, RN - 418-649-0252 -
CHUS Hopital Fleurimont
Sherbrooke, Quebec, Canada
Status: Recruiting
Contact: Anick Champoux, Research coordinator - 819-346-1110 -
Start Date
October 2008
Completion Date
October 2011
Centre Hospitalier Universitaire de Sherbrooke
Centre Hospitalier Universitaire de Sherbrooke
Record processing date processed this data on July 28, 2015 page